Trial Number




Participant Age Range

1 year to 25 years

Participant Gender


Enrolling Participants



AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly

With advances in risk-stratification for patients with B-ALL, overall outcomes have improved remarkably in recent decades with current survival rates of approximately 90%. However, certain subgroups have inferior outcomes, including those with adverse genetic lesions or slow response to initial therapy. For these patients, intensification of classic conventional chemotherapeutic agents has proven too toxic or has failed to improve survival rates. In contrast, targeted immunotherapies demonstrate impressive response rates in heavily pre-treated populations and may lead to higher cure rates without excessive toxicity. InO is an antibody drug conjugate (ADC) composed of a humanized IgG monoclonal CD22-targeted antibody linked to calicheamicin, a potent antitumor antibiotic. The purpose of this phase 2 study is to determine, in a randomized manner, if the addition of 2 blocks of inotuzumab ozogamicin to modified Berlin-Frankfurt-Münster (mBFM) chemotherapy will improve 5-year disease-free survival (DFS) in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).


Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.